Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1620-1627

  Martinive, Philippe ^a   De Wever, Julie ^a   Bouzin, Caroline ^a   Baudelet, Christine ^b   Sonveaux, Pierre ^a   Grégoire, Vincent ^c   Gallez, Bernard ^b   Feron, Olivier ^a  

^a UCL   (Belgium)

^b Medicinal Chemistry and Radiopharmacy Unit   (Belgium)

^c Center for Molecular Imaging and Experimental Radiotherapy   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOPHOSPHAMIDE; DYE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; AUTOCRINE EFFECT; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FIBROSARCOMA; LEWIS CARCINOMA; LIVER TUMOR; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMOOTH MUSCLE RELAXATION; STAINING; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; ARTERIOLES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD VESSELS; CYCLOPHOSPHAMIDE; DRUG DELIVERY SYSTEMS; ENDOTHELIN-1; IN SITU NICK-END LABELING; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MUSCLE RELAXATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ENDOTHELIN A;

EID: 33746086723     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0472     Document Type: Article

References (36)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
2. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
3. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004;25:536-42.
4. McCarty MF, Liu W, Fan F, et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003;9:53-8.
5. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
6. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003;162:183-93.
7. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-93.
8. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6.
9. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-8.
10. Dewhirst MW, Kimura H, Rehmus SW, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 1996;27: S247-51.
11. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumours using T2*-weighted gradientecho imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004;49: 3389-411.
12. Dewhirst MW, Braun RD, Lanzen JL. Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. Int J Radiat Oncol Biol Phys 1998; 42:723-6.
13. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995;71: 1210-3.
14. Patan S, Tanda S, Roberge S, Jones RC, Jain RK, Munn LL. Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation. Circ Res 2001;89:732-9.
15. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
16. Bell KM, Prise VE, Chaplin DJ, Wordsworth S, Tozer GM. Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer 1997;73:283-9.
17. Bell KM, Chaplin DJ, Poole BA, Prise VE, Tozer GM. Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer 1999;80: 295-302.
18. Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol 1998;8: 151-63.
19. Sonveaux P, Dessy C, Martinive P, et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004;64:3209-14.
20. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26: 143-8.
21. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett 1980;11:63-73.
22. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis 1985;3: 281-94.
23. Sonveaux P, Dessy C, Brouet A, et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 2002;16: 1979-81.
24. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
25. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
26. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 1994;32:714-24.
27. Baudelet C, Gallez B. Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment. Magn Reson Med 2003;49:985-90.
28. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987;47:597-601.
29. Minchinton AI, Durand RE, Chaplin DJ. Intermittent blood flow in the KHT sarcoma-flow cytometry studies using Hoechst 33342. Br J Cancer 1990;62:195-200.
30. Pigott KH, Hill SA, Chaplin DJ, Saunders MI. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 1996;40:45-50.
31. Durand RE, Aquino-Parsons C. Non-constant tumour blood flow-implications for therapy. Acta Oncol 2001;40:862-9.
32. Mollica F, Jain RK, Netti PA. A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003;65:56-60.
33. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
34. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Aced Sci U S A 1999;96:3137-42.
35. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003;63: 2447-53.
36. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-4.